Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Status Recruiting

Clinical Trial Summary

The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.

Clinical Trial Description

A multicenter, single-arm, prospective, open-label study to detect the efficacy and safety of flumatinib by measuring rates of major molecular response (MMR) at 12 months in CML-CP patients with Ph+ in China. Approximately 200 Patients will be recruited consecutively from the study sites during the enrollment period and will be given flumatinib 600 mg QD. The duration of patient participation will be 24 months. ;

Study Design

Related Conditions & MeSH terms

Chronic Myeloid Leukemia, Chronic Phase
Flumatinib
Imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trial Details

NCT number	NCT04677439
Study type	Interventional
Source	Shenzhen Second People's Hospital
Contact	Xin Du, Phd
Phone	075583366388
Email	duxingz@medmail.com.cn
Status	Recruiting
Phase	Phase 4
Start date	January 1, 2021
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06409936` - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML	Phase 2
Terminated	`NCT04006847` - Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia	Phase 1/Phase 2
Not yet recruiting	`NCT06368414` - A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia	Phase 2
Active, not recruiting	`NCT04126681` - A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase	Phase 2
Not yet recruiting	`NCT05543161` - "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
Recruiting	`NCT05638763` - Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia	Phase 2
Recruiting	`NCT03610971` - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors	Phase 2
Completed	`NCT03332511` - Efficacy and Safety of Nilotinib in CML-CP	Phase 4
Active, not recruiting	`NCT06233890` - The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Completed	`NCT03882281` - Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia	Phase 1
Recruiting	`NCT03459534` - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	Phase 3
Completed	`NCT03885830` - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Active, not recruiting	`NCT04147533` - Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia	Phase 2
Recruiting	`NCT03942094` - Nilotinib for First-line Newly Diagnosed CML-CP Patients	Phase 3
Active, not recruiting	`NCT03933852` - Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Recruiting	`NCT05311943` - Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.	Phase 3
Active, not recruiting	`NCT04160546` - Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)	Phase 2
Active, not recruiting	`NCT03722420` - Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)	Phase 3
Not yet recruiting	`NCT06163430` - CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia	Phase 1
Completed	`NCT02977312` - Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan	N/A